The Patent Trial and Appeal Board (PTAB) has become the busiest forum for patent disputes nationwide, and Fish & Richardson is a constant presence there. We have handled more inter partes review (IPR) proceedings than any other firm, consistently outpacing our competitors.

Back to Post-Grant

Inter Partes Review

USPTO Details Broad Principles of Discretionary Denial in AIA Proceedings

Teva v. Lilly: Conflicting Positions at PTAB and District Court Sink Patent Challenge

2025 Post-Grant Annual Report

Congressional Oversight Hearing Highlights Continued PTAB Policy Fault Lines

Federal Circuit Denies All Mandamus Petitions Challenging Discretionary Denial Policies

USPTO Adds Three New Factors to Discretionary Denial Considerations

Biologics and Biosimilars Landscape 2025: IP, Policy, and Market Developments

How To Kill a Weak Patent: 10 Strategies After Being Sued

Lessons From Recent Pharma & Med Device Federal Circuit Decisions

Federal Circuit Declines To Disturb “Settled Expectations” Factor in Denying Mandamus Petitions